Delays Related to Prior Authorization in Inflammatory Bowel Disease.

ABSTRACT:

Background

Delays in advancing to biologic therapies are associated with adverse outcomes in inflammatory bowel disease (IBD). Insurer-mandated prior authorizations have been linked to prolonged medication initiation times. We hypothesized that prior authorizations are associated with prolonged biologic initiation time and increased IBD-related healthcare utilization among children with IBD.

Methods

We performed a retrospective cohort study of 190 pediatric patients with IBD initiating biologics at a tertiary care hospital to measure the association between prior authorization, biologic initiation time (physician recommendation to first dose), and healthcare utilization (hospitalization, surgery, or emergency department visit). Demographic, insurance, and disease severity-re

SUBMITTER: Constant BD 

PROVIDER: S-EPMC10234594 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature